Architect Therapeutics
PrivateTotal Funding Raised
$120M
Company Overview
Architect Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. It has raised $120M.
Architect Therapeutics is a biotechnology company that develops oral small-molecule therapies by utilizing carbon-hydrogen (C-H) bond activation chemistry to target challenging disease drivers.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Architect Therapeutics Comparables
Compare Architect Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Belharra Therapeutics | 87% | |
| Neomorph | 83% | |
| BridGene Biosciences | 82% |
For institutional investors. Book with your work email.
Architect Therapeutics Funding Rounds
Historical fundraising activity
Architect Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series A |
| Frazier Healthcare Partners | Series A |
| OrbiMed | Series A |
| Northpond Ventures | Series A |
| ARCH Venture Partners | Series A |
| Viking Global Investors | Series A |
| HongShan Capital Group (HSG) | Series A |
Architect Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Architect Therapeutics's valuation, stock price, and market status.
Is Architect Therapeutics a public or private company?
Architect Therapeutics is a private company.
What is the current stock price of Architect Therapeutics?
Architect Therapeutics is a private company, so its shares have no public market price. Caplight tracks Architect Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Architect Therapeutics worth (valuation)?
Valuation information for Architect Therapeutics is not publicly available.
Can I buy Architect Therapeutics stock?
Architect Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Architect Therapeutics's last funding round?
Funding round information for Architect Therapeutics is not publicly available.
Who are the main investors in Architect Therapeutics?
Key investors in Architect Therapeutics include ARCH Venture Partners.
Will Architect Therapeutics IPO soon?
No public IPO plans have been announced for Architect Therapeutics.
How can I track Architect Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Architect Therapeutics's shares on secondary markets.